Navigation Links
Arteriocyte Receives FDA Approval to Initiate Compartment Syndrome Trial for Amputation Prevention Focused on Wounded Warriors
Date:4/6/2012

CLEVELAND, April 6, 2012 /PRNewswire/ -- Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan MAR01™ technology in the treatment of Compartment Syndrome. The FDA Investigational Device Exemption (IDE 15013) allows Arteriocyte and its clinical partners to initiate evaluation of concentrated marrow injections (using the Magellan MAR01™ technology) to mitigate ischemic damage due to Compartment Syndrome in extremity trauma patients. This treatment has been developed in partnership with the United States Army Institute of Surgical Research (ISR) and San Antonio Military Medical Center (SAMMC) at Fort Sam Houston, and The Ohio State University as part of Arteriocyte's Cellular Therapies for Battlefield Wounds Program.

The Magellan® system is an FDA 510(k) cleared medical device for the rapid production of platelet rich plasma from blood and bone marrow that can be applied to a surgical site as surgeons deem necessary for their clinical use requirements. Magellan MAR01™ technology enables the rapid Operating Room based "closed system" concentration of aspirated bone marrow, yielding an injectable tissue rich in platelets, hematopoietic stem cells and mesenchymal stem cells in as little as fifteen minutes. The self contained Magellan unit provides critical ease-of-use and operator-independent consistency necessary for deployment in military medical operations. Arteriocyte has partnered with the U.S. Military to develop Magellan MAR01™ in clinical use across three trauma platforms: Extremity Trauma, Burn Wounds and Infection Prevention. The company is already actively enrolling patients in a separate clinical trial for MAR01™ treatment in Critical Limb Ischemia under an FDA approved Investigational Device Exemption (IDE-14522).

The current clinical
'/>"/>

SOURCE Arteriocyte
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arteriocyte Takes the Lead in Promoting Building Future Pipeline of Women in STEM Career Fields
2. Arteriocyte Receives $1 Million Award From Ohio Third Frontier Program to Advance Its NANEX™ Technology Toward Clinical Use
3. Arteriocyte and the U.S. Army Institute of Surgical Research (USAISR) Sign a CRADA to Speed Development of Cellular Therapies for Orthopaedic Trauma
4. Arteriocyte Receives FDA Approval to Move Forward with Critical Limb Ischemia Trial
5. Arteriocyte Named Top Biotech Start Up Venture by the Ohio Venture Association for 2010
6. Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor
7. Rensselaer professor Jie Lian receives NSF CAREER Award
8. Islet Sciences Announces DiaKine Therapeutics Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection
9. Watsons Generic BONIVA® 150mg Receives FDA Approval
10. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
11. Foundation of UMDNJ Receives Grand Challenges Tuberculosis Biomarkers Grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... OH (PRWEB) January 22, 2015 Crystal Diagnostics ... today that it has received AOAC-PTM Certifications for the six ... O121, and O145; collectively referred to as STEC or the ... 1 colony forming unit (cfu) per 325 g of raw ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Dr. Greg Leyer ... 12th annual Scripps Natural Supplements Pre-Conference seminar on probiotics in ... is an annual continuing education conference for health care professionals. ... included the topic of probiotics in health. Dr. Leyer spoke ...
(Date:1/22/2015)... 2015 Diagenode, Inc., a leading ... Bioruptor® and complete solutions for epigenetics research, recently ... alleviating the need for manual processing. The new ... ChIP of histones or transcription factors and a ...
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... has been honored for its commitment to sustainability with inclusion ... Varian is the highest ranked healthcare equipment company among the ... during the World Economic Forum at Davos, Switzerland ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Varian Honored Among World's 100 Most Sustainable Corporations 2
... Calif., Jan. 20, 2011 Masimo (Nasdaq: ... study demonstrating the clinical accuracy and value of its ... presented this week at the Society of Critical ... San Diego. The largest multi-professional critical care event of ...
... / -- Cognition Therapeutics Inc., a drug discovery company ... on a $2.5 million Series A1 financing it will use ... New Drug (IND) candidate status. The round was led by ... and was syndicated with Tech Coast Angels.   ...
... NEW YORK, Jan. 20, 2011 Reportlinker.com announces ... in its catalogue: Hospital General ... This is the most comprehensive ... General Radiology and radiology IT systems (PACS) in ...
Cached Biology Technology:New Clinical Study Finds Masimo Noninvasive Hemoglobin Accurate in Patients with Critically Low Hemoglobin Levels 2New Clinical Study Finds Masimo Noninvasive Hemoglobin Accurate in Patients with Critically Low Hemoglobin Levels 3New Clinical Study Finds Masimo Noninvasive Hemoglobin Accurate in Patients with Critically Low Hemoglobin Levels 4New Clinical Study Finds Masimo Noninvasive Hemoglobin Accurate in Patients with Critically Low Hemoglobin Levels 5Cognition Therapeutics Completes $2.5M in Series A1 Financing to Advance Alzheimer's Disease Drug Treatment Program 2Cognition Therapeutics Completes $2.5M in Series A1 Financing to Advance Alzheimer's Disease Drug Treatment Program 3Reportlinker Adds Hospital General Radiology Census 2
(Date:1/22/2015)... , Jan. 16, 2015  A man-made form of ... and other mental capabilities in adults with mild cognitive ... study led by researchers at Wake Forest Baptist Medical ... diagnosed with amnesic mild cognitive impairment (MCI) or mild ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ... "Global Wearable Technologies Market and Applications, Opportunities, Industry ... Forecast 2014-2020" report to their offering. ... that can be worn on the user,s body ...
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research and ... the addition of the "The Global Watermarking ... http://photos.prnewswire.com/prnh/20130307/600769 ... global digital media watermarking and fingerprinting markets. Watermarking ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2
... (Durham, NC April 12, 2010) -- ... Research Center will hold its 2010 Decontamination Research ... the Hilton Raleigh-Durham Airport Hotel in North Carolina. ... decontamination of indoor and outdoor areas and of ...
... in crop lands is a key factor that is ... to a paper published in the International Journal ... global issues include carbon footprints, water resources and climate ... is often overlooked in the global context. Biologist ...
... death globally and a tremendous burden on the healthcare ... and other blood vessels before symptoms occur is needed. ... researchers from Virginia Tech and GE Global Research Center ... methods, including a newly patented approach to a long-standing ...
Cached Biology News:Calculating agriculture's phosphorus footprint 2New patented technology for improving cardiac CTs receives NIH support 2New patented technology for improving cardiac CTs receives NIH support 3New patented technology for improving cardiac CTs receives NIH support 4New patented technology for improving cardiac CTs receives NIH support 5
Anti-Ephrin B1 Host: rabbit polyclonal Species Reactivity: human Applications: WB Storage: 4C...
Rabbit monoclonal [EP881Y] to EEF2K ( Abpromise for all tested applications). Antigen: Synthetic peptide corresponding to residues in the C-terminal of human EEF2K. Entrez GeneID: 29904 S...
...
Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
Biology Products: